Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Oncology Specialists, SC
mi
from
Park Ridge, IL
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Central Indiana Cancer Centers
mi
from
Fishers, IN
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Central Indiana Cancer Centers
mi
from
Fishers, IN
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Indiana University Cancer Center
mi
from
Indianapolis, IN
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Hutchinson Clinic
mi
from
Hutchinson, KA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Hutchinson Clinic
mi
from
Hutchinson, KA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Kentucky Cancer Clinic
mi
from
Hazard, KY
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
St Joseph Oncology
mi
from
Saint Joseph, MO
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
St Joseph Oncology
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Blumenthal Cancer Center
mi
from
Charlotte, NC
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Providence Portland Medical Center
mi
from
Portland, OR
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Lowcountry Hematology and Oncology, PA
mi
from
Mount Pleasant, SC
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Lowcountry Hematology and Oncology, PA
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Thompson Cancer Survival Center
mi
from
Knoxville, TN
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Thompson Cancer Survival Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Virginia Cancer Institute
mi
from
Richmond, VA
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated:  10/24/2014
Local Institution
mi
from
Buenos Aires,
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Status: Enrolling
Updated: 10/24/2014
Local Institution
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma
Status: Enrolling
Updated:  1/13/2015
UCLA
mi
from
Los Angeles, CA
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma
Status: Enrolling
Updated: 1/13/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma
Status: Enrolling
Updated:  1/13/2015
Billings Clinic
mi
from
Billings, MT
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma
Status: Enrolling
Updated: 1/13/2015
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma
Status: Enrolling
Updated:  1/13/2015
Cancer Center of the Carolinas
mi
from
Greenville, SC
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma
Status: Enrolling
Updated: 1/13/2015
Cancer Center of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations
Status: Enrolling
Updated:  1/21/2015
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations
Status: Enrolling
Updated: 1/21/2015
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Infrared Lymphangiography as a Method of Sentinel Node Identification
Status: Enrolling
Updated:  4/27/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Infrared Lymphangiography as a Method of Sentinel Node Identification
Status: Enrolling
Updated: 4/27/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
Veterans Administration Hospital - Martinez
mi
from
Martinez, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
Veterans Administration Hospital - Martinez
mi
from
Martinez, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated:  7/1/2015
Tom Baker Cancer Centre
mi
from
Calgary,
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)
Status: Enrolling
Updated: 7/1/2015
Tom Baker Cancer Centre
mi
from
Calgary,
Click here to add this to my saved trials
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
A Phase I Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
Status: Enrolling
Updated:  7/7/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
A Phase I Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
Status: Enrolling
Updated: 7/7/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Graham Hospital
mi
from
Canton, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Memorial Hospital
mi
from
Carthage, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Eureka Community Hospital
mi
from
Eureka, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Mason District Hospital
mi
from
Havana, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated:  7/9/2015
Kewanee Hospital
mi
from
Kewanee, IL
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung
Status: Enrolling
Updated: 7/9/2015
Kewanee Hospital
mi
from
Kewanee, IL
Click here to add this to my saved trials